NEW YORK (GenomeWeb News) - Solexa provided some insight last week into how it intends to tackle the next-generation sequencing market in the wake of its OEM reagent agreement with Invitrogen. In a presentation to investors, Solexa CEO John West said that the company has identified around 100 potential customers that it will initially target for its instrument.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.